Phase 1 N=12 Mindfulness-Based Ecological Momentary Intervention For Smoking Cessation Among Cancer Survivors
Any Cancer Type
Primary: Retention Rate — 91.7 percentage of Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=15 Pembrolizumab (MK-3475) in Hepatocellular Carcinoma
BCLC Stage B Hepatocellular Carcinoma · BCLC Stage C Hepatocellular Carcinoma · Hepatitis C Infection
Primary: Correlation of HCC Stiffness to Overall Survival — 0.12 kilopascals — p=0.008
Phase 2 N=31 Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma
Advanced Melanoma · Unresectable Melanoma
Primary: Overall Response Rate (ORR) — 10 percentage of patients
N/A N=79 Vaginal Breech Birth Management Educational Mobile Game
Vaginal Breech Delivery Management · Mobile Game
Primary: Evaluation of the Effectiveness of Vaginal Breech Birth Management Serious Mobile Game — 36.51; 34.75; 40.46; 37.77 units on a scale
Phase 1 N=120 BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
Prostatic Neoplasms, Castration-Resistant
Primary: Phase Ib Escalation Part: Number of Patients With Dose Limiting Toxicities (DLTs) — 0; 0 Participants
N/A N=30 Comparison of Low and High Tidal Volumes in Acute Spinal Cord Injury
Spinal Cord Injuries
Primary: Number of Episodes of Pneumonia — .13; .4 episodes of pneumonia
Phase 3 N=400 Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines
COVID-19
Primary: Participants With Solicited Local and Systemic AEs for 7 Days Following Vaccination — 153; 166; 136; 140 participants
N/A N=66 Incorporating Endoscopic Ultrasound and Elastography Towards Improving Outcomes of Pediatric Pancreatitis Management
Chronic Pancreatitis · Acute Recurrent Pancreatitis
Primary: EUS Pancreatic Findings- Rosemont Criteria — 36; 0; 26; 0 percentage of participants
Phase 2 N=234 Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Participants Achieving Clinical Remission (CR) at Week 52 Using Modified Mayo Score (MMS) — 26.0; 18.3 Percentage of participants — p=0.2524
N/A N=72 Memory and Attention Adaptation Training-Geriatrics (MAAT-G) Phase II
Cancer-related Problem/Condition · Cognitive Impairment
Primary: Mean of the Functional Assessment of Cancer Therapy-Cognition (FACT-COG) — 155.8; 152.7 score on a scale
N/A N=60 Improving Uptake and Adherence to HIV Prevention Services With Pre-exposure Prophylaxis (PrEP), HIV Self- Testing and Adherence Support for Very High Risk HIV-negative Young Women Aged 15-24 in Kampala, Uganda
HIV/AIDS
Primary: Initiation of PrEP — 18; 21 Participants
Phase 2 N=173 A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer
Ovarian Neoplasms
Primary: Number of Participants Enrolled Across Cohorts — 41; 36 Participants
N/A N=292 A Hybrid Type 2 Trial of Trauma-Focused Cognitive Behavioral Therapy and a Pragmatic Individual-Level Implementation Strategy
Evidence-Based Practices · CBT · School Health Services
Primary: TF-CBT Adoption and Penetration — 33; 26; 33; 31 Participants — p=0.591
Phase 2 N=27 Is an Antiplaque Chewing Gum (30 mg) Able to Reduce Dental Plaque in a Healthy Population?
Plaque Regrowth
Primary: Safety, Tolerability and Effectiveness in Reducing Dental Plaque of KLS-W Delivered in a Chewing Gum Formulation — 0; 0; 0; 0 participants
N/A N=100 Effect of Electroacupuncture on Opioid-induced Constipation in Patients With Cancer
Opioid-induced Constipation in Patients With Cancer
Primary: Number of Participants With Response — 19; 4 participants